# Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

> **NCT04029038** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- CD19 Positive
- CD22 Positive
- Minimal Residual Disease
- Progressive Disease
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Non-Hodgkin Lymphoma
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT04029038
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-15
- **Primary completion:** 2022-11-16
- **Final completion:** 2022-11-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participant accrual
- **Last updated:** 2023-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04029038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04029038, "Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04029038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*